Vir Biotechnology Inc. (VIR) Misses Q2 EPS by 13c ; Provides outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq edge higher ahead of midterm results; Apple falls
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts VIR Hot Sheet
Join SI Premium – FREE
Vir Biotechnology Inc. (NASDAQ: VIR) reported Q2 EPS of ($1.02), $0.13 worse than the analyst estimate of ($0.89). Revenue for the quarter came in at $3.07 million versus the consensus estimate of $7.53 million.
Outlook:-
GAAP operating expense range: $ 580 to $ 610
For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Block, Inc (XYZ) call put ratio 1 call to 1.6 puts into quarter results
- Iren stock climbs as investors buy ahead of earnings
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
